ARS Pharmaceuticals Inc Sustainability Reports
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of needle-free intranasal therapeutics. Its primary product, neffy, is an intranasal epinephrine spray designed for the emergency treatment of severe Type I allergic reactions, including anaphylaxis.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00FZQGXH2
1 reports from 2023 to 2023
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of needle-free intranasal therapeutics. Its primary product, neffy, is an intranasal epinephrine spray designed for the emergency treatment of severe Type I allergic reactions, including anaphylaxis.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
